Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
16 studies found for:    parp inhibitor ovarian | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Conditions: Advanced Ovarian Cancer;   Primary Peritoneal Cancer;   Advanced Breast Cancer;   Advanced Solid Tumors
Intervention: Drug: BMN 673
2 Recruiting A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Condition: Platinum Sensitive Ovarian Cancer
Interventions: Drug: Active comparator: Niraparib;   Drug: placebo
3 Recruiting Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Veliparib;   Drug: Floxuridine;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
4 Recruiting Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Olaparib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis
5 Recruiting A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Conditions: Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Oral rucaparib
6 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
7 Recruiting Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Conditions: Ovarian Cancer;   Breast Cancer
Intervention: Drug: BKM120 and Olaparib
8 Recruiting mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer
Conditions: Breast Cancer;   Malignant Female Reproductive System Neoplasm
Interventions: Drug: Olaparib;   Drug: AZD2014;   Drug: AZD5363
9 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Veliparib;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
10 Recruiting A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Intervention: Drug: Rucaparib
11 Recruiting Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Conditions: Platinum Sensitive;   BRCA Mutated;   Relapsed Ovarian Cancer;   Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Drug: Olaparib 300mg tablets;   Drug: Placebo to match olaparib 300mg
12 Recruiting Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Conditions: Newly Diagnosed;   Advanced Ovarian Cancer;   FIGO Stage III-IV;   BRCA Mutation;   Complete Response;   Partial Response;   First Line Platinum Chemotherapy
Intervention: Drug: Olaparib 300mg tablets
13 Recruiting Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation
Condition: Recurrent, Epithelial Ovarian Cancer
Intervention: Drug: Veliparib
14 Recruiting A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Rucaparib;   Drug: Placebo
15 Not yet recruiting Phase II Study of BMN 673
Condition: Advanced Cancers
Interventions: Drug: Talazoparib Tosylate;   Behavioral: Phone Call
16 Recruiting Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Carcinosarcoma;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Veliparib;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years